Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

- PMLiVE

UK science could be ‘crippled’ by a hard Brexit

Francis Crick Institute scientists more likely to leave UK post-Brexit

- PMLiVE

Novartis claims a rare win at ESMO for PI3K inhibitor class

Analysts predict drug could hit $1.5bn annual sales

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

How pharma should navigate Artificial Intelligence (AI)

Developing an AI strategy that cuts through the hype

- PMLiVE

Encouraging data for GenSight’s blinding retinal disease gene therapy

Better results after April's setback

- PMLiVE

Lonely planet: why there is dwindling value in pharma travelling alone

To develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward

- PMLiVE

AZ and Clovis PARP inhibitors show their mettle at ESMO

Lynparza and Rubraca both on track to extend cancer patient reach

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

AZ and Medicines Catapult collaborate on innovative sound tech in drug discovery

Collaborates with Medicines Discovery Catapult on AMI-MS

Artificial intelligence in healthcare

What are the benefits for pharma?

- PMLiVE

Shire’s angioedema drug Takhzyro recommended in Europe

Analysts expect the drug to make around $1.8bn in peak sales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links